Press Release

Obsessive-Compulsive Disorder Drugs Market to grow with a CAGR of 7.60%

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Obsessive-Compulsive Disorder Drugs Market.

 

According to TechSci Research report, “Global Obsessive-Compulsive Disorder Drugs Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Obsessive-Compulsive Disorder Drugs Market has valued at USD 882.50 million in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.60% through 2028. This can be due to collaborations and partnerships among leading companies with a diverse approach to merge the expertise of individual companies and to strengthen their position in the market.

Research into the neurobiology of obsessive-compulsive disorder (OCD) is a significant driver for the Global OCD Drugs Market. Understanding the underlying neurobiological mechanisms of OCD is crucial for the development of more effective medications and treatment strategies. Neurobiological research helps identify specific neurochemical pathways and brain regions involved in the development and manifestation of OCD symptoms. This knowledge provides pharmaceutical companies with potential drug targets to develop new medications that can modulate these pathways. Insights from neurobiology research can lead to the development of more targeted therapies. By understanding the neural circuits and neurotransmitter systems involved in OCD, researchers can design drugs that specifically address the underlying causes of the disorder, potentially making them more effective than current treatments. Neurobiological insights may support the development of combination therapies that target multiple aspects of OCD's neurobiology. These combinations can include both pharmacological and non-pharmacological interventions, potentially improving treatment outcomes.

Obsessive-Compulsive Disorder (OCD) is a mental health disorder characterized by the presence of obsessions and compulsions that significantly interfere with a person's daily life and well-being. It is considered an anxiety disorder because it often involves persistent, intrusive thoughts (obsessions) and repetitive behaviors or mental acts (compulsions) aimed at reducing the distress caused by these obsessions. OCD is treatable, and there are several effective treatment approaches, including psychotherapy (particularly Cognitive-Behavioral Therapy with Exposure and Response Prevention, or CBT-ERP) and medications (such as Selective Serotonin Reuptake Inhibitors, or SSRIs). A combination of therapy and medication is often recommended for severe cases.

In June 2022, Brexpiprazole's phase III clinical trial for the management of agitation in patients with Alzheimer's dementia (NCT03548584) has shown encouraging findings, according to Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck). The investigation found that there is a statistically significant difference between brexpiprazole and placebo in the mean change in the Cohen-Mansfield Agitation Inventory (CMAI) total score from baseline to week 12 (p=0.0026). The goal of Trial 331-14-213 (NCT03548584; Trial 213) was to evaluate the effectiveness of two fixed doses of brexpiprazole in the treatment of individuals with agitation associated with Alzheimer's disease. The two dosages were 2 mg/day or 3 mg/day. Patients taking brexpiprazole at doses of 2 mg or 3 mg per day or placebo experienced significantly higher improvements from baseline on the study's primary goal of CMAI (p=0.0026).

The limited efficacy of current treatments is a challenge for the Global Obsessive-Compulsive Disorder (OCD) Drugs Market. While there are various treatment options available for OCD, not all individuals respond equally to these treatments, and a significant proportion of patients may experience only partial relief or no improvement in symptoms. For a substantial number of individuals with OCD, currently available treatments, including medication and psychotherapy, may not adequately alleviate their symptoms. This leaves a significant unmet medical need for more effective treatments. Many current OCD medications are associated with side effects that can be intolerable for some patients. This can lead to treatment discontinuation, reducing the overall effectiveness of available treatments. Not all individuals with OCD respond to medications or psychotherapy in the same way. The variability in treatment response means that there is no one-size-fits-all solution, and alternative treatment options are needed.

 

Browse over XX market data Figures and spread through 110 Pages and an in-depth TOC on "Global Obsessive-Compulsive Disorder Drugs Market.”

 

Global Obsessive-Compulsive Disorder Drugs Market segmentation is based on Type, Application and Region.

Based on Type, Global Obsessive-Compulsive Disorder Drugs Market is segmented into SSRI (Selective Serotonin Reuptake Inhibitors), TCA (Tricyclic Antidepressant). Tricyclic Antidepressants (TCAs) are a class of prescription medications primarily used for the treatment of various mental health conditions, with a focus on depression. They were one of the first types of antidepressants developed and have been in use since the 1950s. While newer antidepressant classes, such as Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), have become more common, TCAs are still prescribed in certain cases when other treatments are ineffective or when their specific effects are desired. TCAs work by increasing the levels of certain neurotransmitters (chemical messengers) in the brain, namely serotonin and norepinephrine. By inhibiting the reuptake of these neurotransmitters, TCAs allow them to remain in the synaptic gap between nerve cells, which can lead to improved mood and reduced symptoms of depression.

Based on Region, North America dominated the Global Obsessive-Compulsive Disorder Drugs Market. North America has a robust network of patient advocacy and support groups dedicated to OCD and related mental health disorders. These organizations raise awareness, provide resources, and advocate for improved access to treatment, further contributing to the prominence of OCD in the region. Pharmaceutical companies in North America have well-established marketing and sales strategies, which can influence the prescription patterns of healthcare providers and promote the use of OCD medications. Over the years, there has been an increased focus on mental health awareness and destigmatization of mental disorders in North America. This has led to more individuals seeking help and being diagnosed with conditions like OCD, thereby driving demand for treatment. In the United States, health insurance coverage is widespread, which helps patients access necessary medications, including those for OCD, more easily. Insurance coverage can significantly reduce the out-of-pocket costs for patients.

Asia-pacific region to fastest growth in the Global Obsessive-Compulsive Disorder Drugs Market. There has been a notable shift in recent years towards increased mental health awareness in many APAC countries. Advocacy campaigns, government initiatives, and the work of mental health organizations have helped reduce stigma, encouraging individuals to seek help for conditions like OCD. As APAC countries industrialize and urbanize, there has been a reported increase in the prevalence of mental health conditions, including OCD. This higher prevalence has driven greater demand for OCD drugs and mental health services. Rapid economic growth in some APAC countries has led to an increase in the middle-class population. This demographic tends to have better access to healthcare services, including mental health treatment, and is more likely to seek treatment for mental health conditions.

 

Some of the major companies operating in the Global Obsessive-Compulsive Disorder Drugs Market include:

  • Abbott SA
  • Eli Lilly, and Company
  • Viatria Inc.
  • H. LUNDBECK A/S,
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Zydus Pharmaceuticals, Inc.
  • Lupin Pharmaceuticals, Inc.
  • Amneal Pharmaceuticals LLC
  • Teva Pharmaceutical industries Ltd.

 

Download Free Sample Report

Customers can also request 10% free customization on this report.

 

“Certain areas, particularly in North America, are projected to exert significant demand for OCD Drugs. The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the Global Obsessive-Compulsive Disorder Drugs Market in the forecast period," said Mr. Karan Chechi, Research Director with TechSci Research, a research-based Global management consulting firm.

Obsessive-Compulsive Disorder Drugs Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Type (SSRI (Selective Serotonin Reuptake Inhibitors), TCA (Tricyclic Antidepressant)), by Application (Research Institute, Hospitals & Clinics, Others), by region, and Competition evaluated the future growth potential of Global Obsessive-Compulsive Disorder Drugs Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Obsessive-Compulsive Disorder Drugs Market.

 

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: www.techsciresearch.com

Relevant News